Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-05-26 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated May 26, 2023, announcing preliminary data from a Phase 1/2 clinical trial (SAR'579/IPH6101) for a drug candidate. It highlights key results (dose escalation, efficacy, safety) and mentions that the data will be presented orally at the ASCO 2023 annual congress. This format—a formal announcement of clinical trial results and upcoming presentation—is characteristic of an Earnings Release (ER) or a general press release detailing operational/scientific progress. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a formal presentation (IP), the most fitting category for the initial release of key financial/operational results is 'Earnings Release' (ER), as clinical trial updates often serve as the primary 'earnings' driver for biotech firms. It is a direct announcement of results, not just an announcement that a report is forthcoming (RPA). FY 2023
2023-05-26 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release dated May 26, 2023, announcing clinical trial highlights (Phase 1/2 dose escalation safety and preliminary efficacy) for a drug candidate (SAR'579 / IPH6101) developed in collaboration with Sanofi. It details preliminary results, mentions an upcoming oral presentation at the ASCO 2023 Annual Meeting, and provides company background and forward-looking statements. This format—a formal announcement of significant operational/clinical progress, often preceding a major conference presentation—is characteristic of an Earnings Release (ER) or a general press release announcing material non-public information. Since it focuses purely on clinical/pipeline updates and partnership milestones rather than comprehensive quarterly financial figures (which would suggest an IR or MDA), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, the most appropriate classification is Earnings Release (ER), as these often contain key operational highlights alongside any financial context, or it could be classified as Regulatory Filing (RNS) if it were purely informational without the 'press release' structure. Given the structure and the focus on key results ('HIGHLIGHTS'), ER is a strong fit, though RNS is a possibility if it's deemed a general corporate update. However, press releases detailing clinical trial progress and upcoming presentations are frequently categorized as ERs when they are the primary means of disseminating period-specific operational news outside of mandatory financial reports. Since it is a formal announcement of results, I will classify it as ER, as it functions as a results announcement. FY 2023
2023-05-26 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-05-23 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "PROCHAINS RENDEZ-VOUS INVESTISSEURS D'INNATE PHARMA" (Upcoming Investor Meetings of Innate Pharma) and lists several upcoming conferences (ASCO, Jefferies, Goldman Sachs, Stifel) where management will be present between June 2 and June 30, 2023. This is an announcement detailing future engagements with investors, not a full financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing or Dividend Notice. It serves to inform investors about where management will be available for discussions, which aligns best with general Investor Relations communication, often categorized under Investor Presentation (IP) if it were a deck, or more broadly as a communication about investor engagement. Since the core purpose is announcing management's schedule for investor conferences, it is most closely related to Investor Presentation (IP) materials or general investor communication. Given the options, and that it is an announcement about future investor interactions rather than a formal report or transcript, 'Investor Presentation' (IP) is the closest fit, although 'Regulatory Filings' (RNS) could also be considered if the intent was purely administrative. However, because it details specific investor engagement events, IP is a stronger thematic fit than the general fallback RNS.
2023-05-23 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that members of the senior management team are scheduled to participate in several upcoming investor conferences (ASCO, Jefferies, Goldman Sachs, Stifel). This type of announcement, which details future investor engagement events rather than releasing financial results, management changes, or regulatory filings, is best classified as an Investor Presentation (IP) or a general communication aimed at investors. Since 'Investor Presentation' (IP) is defined as a detailed presentation focusing on financials, strategy, and market position, and this document is an announcement *about* future participation in investor events, it strongly aligns with investor relations communication. However, none of the codes perfectly capture 'Announcement of Conference Participation'. Given the options, 'Investor Presentation' (IP) is the closest fit as it relates directly to scheduled investor outreach and market positioning discussions. Alternatively, if this were a very short announcement linking to a presentation, it might be RPA or RNS, but this text is substantial and details the events. Since it is an announcement regarding future investor engagement, IP is the most appropriate category among the choices provided, as it is a proactive communication to the investment community.
2023-05-23 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.